Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Conditions

• Gram Negative Pneumonia
• Gram-Negative Bacterial Infections
• Bacteremia Caused by Gram-Negative Bacteria

Interventions

• DRUG: Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
• OTHER: Placebo

Sponsor

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation